Intellipharmaceutics (IPCI) trading halted with news pending
- Stocks face worst month since September, yen swings after BoJ
- Microsoft fiscal Q3 results top estimates as AI revolution spurs cloud growth
- Alphabet stock surges 11% to record high on Q1 earnings beat, first-ever dividend
- Intel slides in afterhours trading as Q1 revenue misses, Q2 outlook falls short
- Oil prices on track to snap two-week losing streak
- Rubrik (RBRK) Prices Upsized 23.5M Share IPO at $32/sh
- Union Pacific beats profit estimates on stronger pricing, resumes share buyback
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hertz Global (HTZ) misses earnings expectations as fleet costs weigh
- Teladoc (TDOC) Misses Q1 EPS by 3c, offers outlook
- After-hours movers: Alphabet, Microsoft, Snap, Intel, and more
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
Maxim Group Reiterates Buy, $6 PT on IntelliPharmaCeutics (IPCI) as FDA Greenlights Generic Seroquel XR
October 10, 2016 7:36 AM EDTMaxim Group analyst Jason Kolbert reiterated a Buy rating and $6 price target on IntelliPharmaCeutics International (NASDAQ: IPCI) after announced on Friday that the company received tentative approval from the FDA for generic Seroquel XR (quetiapine fumarate extended-release tablets) in the 50, 150, 200, 300, and 400mg strengths.
Kolbert highlighted:
Intellipharmaceutics announced on Friday that the company received tentative approval from the FDA for generic Seroquel XR (quetiapine fumarate extended-release tablets) in the 50, 150, 200, 300, and 400mg... More